Baudax Bio/Recro

At a price of $94 this will be a tough sell. Previous IV NSAID launches at lower prices have failed badly. Hospitals will delay making a decision until HTX-011 is released so that they can review both drugs at once and by then, generic Offirmev will be just months away.

 

Tough environment to launch a new drug with generic competition. Baudax Bio has a head start advantage but that gap tightens since they can't really do much until the COVID 19 virus is resolved or at least under reasonable control. Absolutely necessary to hire experienced territory managers with an established network of contacts to hit the ground running. Good luck to all.

 

Elective surgeries cancelled due to COVID-19. Outpatient surgery strategy is a dead end.

 

Possibly, but do you think that switching strategies to focus on hospital is better? Their stock is way down, primarily because they just did a new offering.

 

Focussing on hospitals would be great if they can afford it. Totally depends on the specific markets. Public healthcare systems especially heavy 340B accounts are going to be a really hard sell. This is a horrible time to launch this product. Recro just can't catch a break. Third time finally approved and now COVID 19. Too bad.

 

Good point. Still wishing them the best.

 

Does anyone have any feedback on the current outstanding territories available for hire at Baudax? Where is everyone in the process? Thanks in advance. Looking forward to the feedback before making a key decision